On December 11, 2014, the U.S. Food and Drug Administration released a Safety Announcement warning that the antipsychotic drug Geodon® is associated with serious skin reactions which can progress to affect other parts of the body. A new warning has been added to the Geodon® (ziprasidone) warning label to describe the serious condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Patients who have a fever with a rash and/or swollen lymph glands should seek urgent medical care. Health care professionals should immediately stop treatment with Geodon® if DRESS is suspected.
Ziprasidone is an antipsychotic drug used to treat the serious mental health disorders schizophrenia and bipolar I disorder. Ziprasidone helps restore certain natural substances in the brain and can decrease hallucinations, delusions, other psychotic symptoms, and mania. To work properly, ziprasidone should be taken every day as prescribed. Patients should not stop taking their medicine or change their dose without first talking to their health care professional.
DRESS may start as a rash that can spread to all parts of the body. It can include fever, swollen lymph nodes, and inflammation of organs such as the liver, kidney, lungs, heart, or pancreas. DRESS also causes a higher-than-normal number of a particular type of white blood cell called eosinophils in the blood. DRESS can lead to death.
Peterson & Associates, P.C. is investigating claims against the manufacturer of Geodon® for failing to warn patients of this serious and potentially deadly side effect.
Geodon lawsuits are complex and you need an experienced Geodon attorney on your side.
Uses: Schizophrenia, Psychosis, Bipolar Mania
Antipsychotic medications are used to treat a wide variety of psychotic illnesses. First-Generation Antipsychotics (FGAs) are widely available and used for treating psychosis symptoms, such as delusions and hallucinations.
Second Generation Antipsychotics (SGAs), also referred to as Atypical Antipsychotics, are used to treat negative symptoms (such as withdrawal, poverty of speech, apathy or the like), cognitive and affective symptoms and to treat schizophrenia.
There are currently six (6) available SGAs, including Zyprexa®, Clozaril®, Risperdal®, Seroquel®, Geodon®, and Abilify®. Recently, the FDA required all of the manufacturers of Atypical Antipsychotics to add warnings about the increased risk of developing diabetes or hyperglycemia (increased blood sugars).
Several medical associations have urged users of SGAs to be watched carefully to ensure that they are not developing diabetes.